Abstract Number: 2921 • 2017 ACR/ARHP Annual Meeting
Improved Survival Following Renal Transplantation in Waitlisted Patients with Systemic Lupus Erythematosus in the United States
Background/Purpose: Lupus nephritis is a major complication of systemic lupus erythematosus (SLE), occurring in up to half all SLE patients and progressing to end-stage renal…Abstract Number: 28 • 2017 Pediatric Rheumatology Symposium
Dyslipidemia in Juvenile Dermatomyositis
Background/Purpose: Juvenile Dermatomyositis (JDM) is a multisystem pediatric autoimmune disease characterized by chronic inflammation of muscle and skin. Premature atherosclerosis is an important cause of…Abstract Number: 21 • 2017 Pediatric Rheumatology Symposium
Enhancing Quality of Care in Childhood-Onset Systemic Lupus Erythematosus by Improving Performance on Quality Indicator Measures in Cardiovascular and Bone Health
Background/Purpose: Childhood-onset SLE (cSLE) leads to poor health outcomes, including cardiovascular and bone health, due to high rates of potentially devastating disease complications and medication…Abstract Number: 1L • 2016 ACR/ARHP Annual Meeting
The Cardiovascular Safety of Celecoxib Versus Ibuprofen or Naproxen in 24,081 Patients with Osteoarthritis or Rheumatoid Arthritis
*Both authors (Husni, Solomon) contributed equally and will co present Background/Purpose: The relative cardiovascular (CV) safety of non-selective NSAIDs and selective COX-2 NSAIDs remains unclear. Given…Abstract Number: 29 • 2016 ACR/ARHP Annual Meeting
Risk of Vascular Mortality in Seniors with New-Onset Rheumatoid Arthritis
Background/Purpose: RA patients are known to be at increased risk of vascular morbidity and mortality, although conflicting reports exist for incident RA patients. Our aim…Abstract Number: 877 • 2016 ACR/ARHP Annual Meeting
Risk of Coronary Artery Disease in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis
Risk of Coronary Artery Disease in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-analysis Background/Purpose: Several chronic inflammatory disorders, such as rheumatoid arthritis and…Abstract Number: 1474 • 2016 ACR/ARHP Annual Meeting
Increased Levels of Lipoprotein(a) in RA Patients with Cardiovascular Disease
Background/Purpose: Patients with various inflammatory rheumatic diseases (IRD) have increased cardiovascular morbidity caused by atherosclerosis. The aetiology of the accelerated atherosclerosis in IRD is still…Abstract Number: 1653 • 2016 ACR/ARHP Annual Meeting
Delineating the Effects of Rheumatoid Arthritis Pharmacotherapies on Vascular Inflammation: Rationale and Design of a Clinical Trial
Background/Purpose: Rheumatoid arthritis is associated with an excess cardiovascular disease (CVD) burden. Fewer CVD events associated with specific DMARD therapies have been reported; however, causal…Abstract Number: 2291 • 2016 ACR/ARHP Annual Meeting
Impact of Plasma Urate and Tophaceous Burden on Inflammatory Biomarkers of Cardiovascular Disease
Background/Purpose: Gout and hyperuricemia have been associated with cardiovascular disease. Studies have documented the impact of serum urate levels on hypertension and that increased urate…Abstract Number: 69 • 2016 ACR/ARHP Annual Meeting
IL-32 Promoter SNP rs4786370 Predisposed to Modified Lipoprotein Profiles in Patients with Rheumatoid Arthritis
Background/Purpose: Patients with a chronic inflammatory disease such as rheumatoid arthritis (RA) are at higher risk of developing cardiovascular diseases (CVD). Interleukin (IL)-32 has previously…Abstract Number: 881 • 2016 ACR/ARHP Annual Meeting
Cardiopulmonary Involvement in Takayasu Arteritis
Background/Purpose: Takayasu arteritis (TAK) is an inflammatory large-vessel vasculitis of unknown etiology affecting the proximal aorta and its primary branches. Heart disease is a major…Abstract Number: 1475 • 2016 ACR/ARHP Annual Meeting
Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Non-Selective Nsaids in Taiwanese Rheumatoid Arthritis Patients
Background/Purpose: Topical NSAIDs (tNSAIDs) have less systemic absorption than oral NSAIDs (oNSAIDs). Thus, tNSAIDs may be associated with a reduced cardiovascular disease (CVD) risk compared…Abstract Number: 1714 • 2016 ACR/ARHP Annual Meeting
Risk of 10-Year Cardiovascular Disease Assessed By Framingham Risk Score Is Similar in Patients with Psoriatic Arthritis and Psoriasis As Assessed By Atherosclerotic Cardiovascular Disease and Framingham Risk Scores
Background/Purpose: Patients with psoriatic arthritis (PsA) and psoriasis (PsO) are at increased risk of cardiovascular diseases (CVD) and the risk is higher in patients with…Abstract Number: 2293 • 2016 ACR/ARHP Annual Meeting
Cardiometabolic Risk and Subclinical Urate Deposits in Patients with Symptomatic Hyperuricemia and Metabolic Syndrome
Background/Purpose: Elevated serum uric acid (sUA) levels, with and without gout, are associated with systemic inflammation, coronary artery disease (CAD), chronic kidney disease, and diabetes.…Abstract Number: 128 • 2016 ACR/ARHP Annual Meeting
Call to Action: Cardiovascular Comorbidities in Medicare Rheumatology Beneficiaries
Background/Purpose: Cardiovascular (CV) manifestations of Rheumatological inflammatory diseases have become increasingly recognized, and, in some patients, might even constitute the initial presentation of a Rheumatological…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 38
- Next Page »